In the LEADER study (the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome), the first study of positive cardiovascular outcomes of GLP1-RA, systolic BP was lower (-1.2 mm Hg), but diastolic BP was higher (+ 0.6 mm Hg), and heart rate (+ 3.0 beats per minute) was increased in the liraglutide group compared to the placebo group [69]. The gene discussed is GCG; the disease is diabetes mellitus.